Published on 16 Dec 2021 on Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Calliditas Therapeutics AB (publ)'s (NASDAQ: CALT) announced the U.S. Food and Drug Administration has approved Tarpeyo delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression.